Floating drug delivery of antidiabetic drugs: An overview

International Journal of Pharma and Bio Sciences

Volumn 3, Issue 4, 2012, Pages 456-471

  Sharma, Megha ^a   Kohli, Seema ^b  

^a Shri Ram Institute of Technology   (India)

^b KN Polytechnic College   (India)

Author keywords

Antidiabetic drugs and gastric emptying; Bioavailability; Floating system

Indexed keywords

ACRYLIC ACID RESIN; AGAR; ANTIDIABETIC AGENT; BICARBONATE; CALCIUM CARBONATE; CALCIUM SILICATE; CARBOMER; CARBOXYMETHYLCELLULOSE; CELLULOSE ACETATE; CHITOSAN; CITRIC ACID; DRUG CARRIER; ETHYL CELLULOSE; EUDRAGIT RS; FLOATING MICROSPHERE; GLIPIZIDE; HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL; METFORMIN; MICROSPHERE; MUCOADHESIVE POLYMER; NATEGLINIDE; PIOGLITAZONE; POLYACRYLIC ACID; POLYCARBONATE; POLYMER; POLYVINYL ACETATE; REPAGLINIDE; ROSIGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; ARTICLE; BILE SECRETION; BIOADHESIVE DRUG DELIVERY SYSTEM; BULK DENSITY; DRUG ABSORPTION; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DEGRADATION; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG ELIMINATION; DRUG FORMULATION; DRUG GRANULE; DRUG HALF LIFE; DRUG MIXTURE; DRUG PENETRATION; DRUG RETENTION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TRANSPORT; EFFERVESCENT TABLET; EXPANDABLE GASTRORETENTIVE DOSAGE FORM; FILM; FLOATING DRUG DELIVERY SYSTEM; GEL; HUMAN; INTESTINE TRANSIT TIME; MAGNETISM; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PATIENT COMPLIANCE; PILL; POWDER; SEDIMENTATION; STOMACH EMPTYING; SUSTAINED DRUG RELEASE; TABLET COMPRESSION;

EID: 84873859045     PISSN: None     EISSN: 09756299     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Hoffman A, Pharmacodynamic aspects of sustained release preparations, Adv. Drug Deliv. Rev., 33 (3): 185-199 (1998).
2. Wilding IR, Prior DV, Remote controlled release capsules in human drug absorption (HDA) studies. Crit. Rev. Ther. Drug Carrier Syst., 20 (6): 405-431 (2003).
3. Corrigan OI, The biopharmaceutic drug classification and drugs administered in extended release ER formulations, Adv. Exp.Med. Biol., 423 (5): 111-128 (1997).
4. Hwang SJ, Park H and Park K, Gastric retentive drug delivery systems, Crit. Rev. Ther. Drug Carrier Syst., 15 (3): 243-284 (1998).
5. Groning R and Heun G, Oral dosage forms with controlled gastrointestinal transit, Drug. Dev. Ind. Pharm., 10 (4): 527-539 (1984).
6. Moes AJ, Gastroretentive dosage forms, Crit. Rev. Ther. Drug Carr. Syst., 10 (2): 143-195 (1993).
7. Deshpande AA, Rhodes CT, Shah NH and Malick AW, Controlled release drug delivery systems for prolonged gastric residence: an overview, Drug Dev. Ind. Pharm., 22 (6): 531-539 (1996).
8. Ming Hu and Xiaoling Li. Oral Bioavailability: Basic Principles, Advanced Concepts, and Applications. In: C.H. Paul, (eds.), Biological and Physiological features of the gastrointestinal tract relevant to oral drug absorption, John Wiley & Sons, Inc., Hoboken, New Jersy, 2011,pp.53.
9. Bardelmeijer HA, Tellingen O, Schellens JH and Beijnen JH, The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery. Invest. New Drugs, 18 (3): 231-241 (2000).
10. Desai S, A Novel Floating Controlled Release Drug Delivery System Based on a Dried Gel Matrix Network [master's thesis]. 1984 Jamaica, NY, St John's University.
11. Vantrappen GR, Peeters TL and Janssens J, The secretory component of interdigestive migratory motor complex in man. J. of Gastroenterol., 14 (7): 663-667 (1979).
12. C.G. Wilson, N. Washington. The stomach: its role in oral drug delivery. In: Rubinstein MH, (eds.), Biological Barriers to Drug Absorption, Chichester, Ellis Horwood, UK, 1989, pp.47-70.
13. Gruber P, Rubinstein A, Li VH, Bass P and Robinson JR, Gastric emptying of nondigestible solids in the fasted dog, J. of Pharm. Sci., 76 (2): 117-122 (1987).
14. Tadataka Yamada, David H. Alpers, Anthony N. Kalloo, Neil Kaplowitz, Chung Owyang and Don W. Powell, Ed. Textbook of Gastroenterology II, 5th Edn, Vol. 1, J.B. Lippincott, Philadelphia: 181-206, 1995.
15. Minami H and McCallum RW, The physiology and path physiology of gastric emptying in humans, Gastroenterology, 86 (7): 1592-1610 (1984).
16. Desai S and Bolton S, A floating controlled release drug delivery system: in vitro- in vivo evaluation, Pharm Res., 10 (*): 1321-1325 (1993).
17. N Washington, C Washington and C.G. Wilson. The stomach. In: Physiological Pharmaceutics, (eds.), Barriers to Drug Absorption, Taylor and Francis, London, 2001,pp.75-108.
18. Davis SS, Formulation strategies for absorption windows, Drug Dev Tech. 10(4): 249-58 (2000).
19. Hou SY, Cowles VE and Berner B, Gastric retentive dosage forms: a review. Crit. Rev. Ther. Drug Carrier Syst., 20 (6): 459-497 (2003).
20. Reddy LH and Murthy RS, Floating dosage systems in drug delivery, Crit. Rev. Ther. Drug Carrier Syst., 19: 553-585 (2002). 21. D.W. Davis. Method of swallowing a pill, U.S. Patent US 3, 418, 999, 1968.
21. D.W. Davis. Method of swallowing a pill, U.S. Patent US 3, 418, 999, 1968.
22. Kawashima Y, Niwa T, Takeuchi H, Hino T and Ito Y, Preparation of multiple unit hollow microspheres (microballoons) with acrylic resin containing tranilast and their drug release characteristics (in vitro) and floating behavior in vivo, J. of Control. Release, 16 (3): 279-290 (1991).
23. Rouge N, Leroux JC, Cole ET, Doelker E and Buri P, Prevention of the sticking tendency of floating minitablets filled into hard gelatin capsules, Eur. J. of Pharm. Biopharm., 43: 165-171 (1997).
24. Hilton AK and Deasy PB, In vitro and in vivo evaluation of an oral sustainedrelease floating dosage form of Amoxicillin Trihydrate, Int. J. of Pharm. 86: 79-88 (1992).
25. K. Ushimaru, K. Nakamichi and H. Saito. Pharmaceutical preparations and a method of manufacturing them, U.S. Patent US 4, 702, 918, 1987.
26. Krogel I and Bodmeier R, Floating or pulsatile drug delivery system based on coated effervescent cores, Int. J. of Pharm., 187: 175-184 (1999).
27. Sheth PR and Tossounian J, The hydrodynamically balanced system (HBSE): a novel drug delivery system for oral use, Drug Dev. Ind. Pharm., 10: 313-339 (1984).
28. Kawashima Y, Niwa T, Takeuchi H, Hino T and Itoh Y, Hollow microspheres for use as a floating controlled drug delivery system in the stomach, J Pharm Sci., 81 (2): 135-140 (1992).
29. Ritschel WA, Targeting in the gastrointestinal tract: new approaches, Methods Find. Exp. Clin. Pharmacol., 13 (5): 313-336 (1991).
30. A.S. Michaels, J.D. Bashwa and A. Zaffaroni. Integrated device for administering beneficial drug at programmed rate, U.S. Patent US 3, 901, 232, 1975.
31. A.S. Michaels. Drug delivery device with self actuated mechanism for retaining device in selected area, U.S. Patent US 3, 786, 813, 1974.
32. A. Rubinstein and D.R. Friend DR. Specific delivery to the gastrointestinal tract. In: Domb AJ (eds.), Polymeric site specific pharmacotherapy, Wiley, Chichester, 1994,pp. 282-283.
33. Garg S and Sharma S, Gastroretentive drug delivery systems, Business Briefing: PharmaTech, 2003, pp. 160-166.
34. A.S. Michaels. Drug delivery device for self actuated mechanism for retaining device in selected area, U.S. Patent US 3786813, 1974.
35. A.S. Michaels. Integrated device for administering beneficial drug at programmed rate, U.S. Patent US 3901232, 1975.
36. Hashim H and Wan PL, Improving the release characteristics of water soluble drugs from hydrophilic sustained release matrices by in situ gas- generation, Int. J. of Pharm., 35: 201-206 (1987).
37. Ichikawa M, Watanabe S and Miyak Y, A new multiple-unit oral floating dosage system. I: Preparation and In-vitro evaluation of floating and sustained release characteristics, J. of Pharm. Sci., 80: 1062-1066 (1991).
38. Klausner EA, Lavy E, Friedman M and Hoffman A, Expandable gastroretentive dosage forms, J. of Control. Release, 90 (2): 143-162 (2003).
39. L.J. Caldwell, C.R. Gardner and R.C. Cargill. Drug delivery device which can be retained in the stomach for a controlled period of time, U.S. Patent US 4735804, 1988.
40. L.J. Caldwell, C. Gardner, R.C. Cargill, and T. Higuchi. Drug delivery device which can be retained in the stomach for a controlled period of time, U.S. Patent US 4758436, 1988.
41. Park K and Robinson JR, Bioadhesive polymers as platforms for oral controlled drug delivery: method to study bioadhesion, Int. J. Pharm., 19 (2): 107-127 (1984).
42. Smart JD, Kellaway IW and Worthington HE, An in-vitro investigation of mucosa adhesive materials for use in controlled drug delivery. J. Pharm. Pharmacol., 36 (5): 295-299 (1984).
43. Klausner EA, Lavy E, Stepensky D, Friedman M and Hoffman A, Novel gastroretentive dosage forms: Evaluation of gastroretentive and its effect on Riboflavin absorption in dogs, Pharm. Res., 19 (10): 1516-1523 (2002).
44. Huang Y, Leobandung W, Foss A and Peppas NA, Molecular aspects of mucoand bioadhesion: tethered structures and site-specific surfaces, J. of Control. Release, 65 (1-2): 63-71 (2000).
45. Vasir JK, Tambwekar K and Garg S, Bioadhesive microspheres as a controlled drug delivery system, Int. J. of Pharm., 255 (1-2): 13-32 (2003).
46. Moes AJ, Gastroretentive dosage forms, Crit Rev. Ther. Drug Carrier Syst., 10: 143-195 (1993).
47. Riner JL, Byford RL, Stratton LG and Hair JA, Influence of density and location on degradation of sustained-release boluses given to cattle, Am. J. of Vet. Res., 43 (11): 2028-2030 (1982).
48. Cardinal JR, Controlled drug delivery: Veterinary applications, J. Control. Release, 2: 393-403 (1985).
49. Moes AJ, Gastric retention systems for oral drug delivery, Business Briefing: PharmaTech, 2003, pp. 157-159.
50. Garg S and Sharma S, Gastroretentive drug delivery systems, Business Briefing: PharmaTech, 2003, pp. 160-166.
51. Ito R, Machida Y, Sannan T and Nagai T, Magnetic granules A novel system for specific drug delivery to esophageal mucosa in oral administration, Int. J. of Pharm., 61 (1-2): 109-117 (1990).
52. Hwang SJ, Park H and Park K, Gastric retentive drug-delivery systems, Crit. Rev. Ther. Drug Carr. Syst., 15 (3): 243-284 (1998).
53. Kamila M, Mondal N, Ghosh KL and Gupta B, Multiunit floating drug delivery system of Rosiglitazone Maleate: Development, characterization, statistical optimization of drug release and In-Vivo evaluation. AAPS Pharm. Sci. Tech., 10 (3): 887-899 (2009).
54. Chaurasia H, Jain AK, Prajapati SK, Chaurasia D, Gupta R, Arya R and Bhardwaj P, Formulation and invitro evaluation of Rosiglitazone Maleate floating microspheres, The Indian Pharmacist, 6 (65): 101-103 (2007).
55. Hu LD, Xing QB, Shang C, Liu W, Liu C, Luo ZL and Xu HX, Preparation of Rosiglitazone maleate sustained-release floating microspheres for improved bioavailability, Pharmazie, 65(7): 477-80 (2010).
56. Rao MR, Borate SG, Thanki KC, Ranpise AA and Parikh GN, Development and invitro evaluation of floating Rosiglitazone maleate microspheres, Drug Dev. Ind. Pharm., 35(7): 834-42 (2009).
57. Shirolkar SV, Tawar MG, Gandhi NS and Deore NB, Development and evaluation of floating microspheres of Pioglitazone hydrochloride using ethyl cellulose, Der Pharmacia Lettre, 2 (5): 261-277 (2010).
58. Jain SK, Agrawal GP, Awasthi AM and Jain NK, Calcium silicate based microspheres of Repaglinide for gastroretentive floating drug delivery: Preparation and in vitro characterization, J. of Controlled Release, 107 (2): 300-309 (2005).
59. Jain SK, Agrawal GP and Jain NK, A novel calcium silicate based microspheres of Repaglinide:In vivo investigations, J. of Controlled Release, 113: 111-116 (2006).
60. Dey S, Kumar D, Kumar S, Sreenivas SA, Rahul V, and Samal HB, Formulation, charcterization and in-vitro evalution of floating microspheres of Nateglinide, Int. J. of Pharm. and Bio. Sci., 2(1): 147-156 (2011).
61. Tripathi M, Radhika PR and Sivakumar T, Formulation and evaluation of Glipizide hollow microballoons for floating drug delivery, Bulletin of Pharm. Res., 1 (1): 67-74 (2011).
62. Sarode SM, Mittal1 M, Magar RM, Shelke AD, Shrivastava B and Vidyasagar G, Formulation and evaluation of floating microspheres of Glipizide, J. Chem. Pharm. Res., 3 (3): 775-783 (2011).
63. Patel A, Ray S and Thakur RS, Invitro evaluation and optimization of controlled release floating drug delivery System of Metformin Hydrochloride, DARU, 14 (2): 57-64 (2006).
64. Nath B, Nath LK, Mazumdar B, Sharma N and Sarkar M, Design and development of Metformin HCl floating microcapsules using two polymers of different permeability characteristics, Int. J. of Pharma. Sci. and Nanotech., 2 (3): 627-637 (2009).
65. Ghodake JD, Vidhate JS, Shinde DA and Kadam AN, Formulation and evaluation of floating microsphere containing Anti- Diabetic Metformin Hydrochloride Drug, Int. J. of PharmTech Res., 2 (1): 378-384 (2010).
66. Salunke P, Rane B, Bakliwal S and Pawar S, Floating Microcarriers of an Antidiabetic Drug: Preparation and its In-Vitro Evaluation, J. of Pharma. Sci. and Tech., 2 (6): 230-240 (2010).
67. Sonara GS, Jaina DK and Moreb DM, Preparation and in vitro evaluation of bilayer and floating-bioadhesive tablets of Rosiglitazone Maleate, Asian J. of Pharma. Sci., 2 (4): 161-169 (2007).
68. Irene N and Sasikanth K, Preparation and in vitro evaluation of Rosiglitazone Maleate bi layered bioadhesive floating tablets, J. Chem. Pharm. Res., 3 (4): 140-149 (2011).
69. Kavitha K, Puneeth KP and Tamizh MT, Development and evaluation of Rosiglitazone Maleate floating tablets, Int. J. of App. Pharma., 2 (2): 6-10 (2010).
70. Nagalakshmi S and Sathalia AH, Formulation and evaluation of Pioglitazone floating drug delivery system, The Indian Pharmacist, 8 (85): 57-66 (2009).
71. Jamzad S and Fassihi R, Development of a controlled release low dose class II drug- Glipizide, Int. J. of Pharma., 312: 24-32 (2006).
72. Sudharshini S, Rathinaraj BS, Bangale GS, Shinde GV and Umalkar DG, Design And Evaluation of sintered Floating Tablets Of Glipizide, Int. J. of Comprehensive Pharmacy, 1 (5): 1-7 (2010).
73. Sivabalan M, Vani TP, Reddy P, Jose A and Nigila G, Formulation and evaluation of gastroretentive Glipizide floating tablets, Int. J. of Comprehensive Pharmacy, 2 (1): 1-4 (2011).
74. Patel JK and Chavda JR, Formulation and evaluation of glipizide floatingbioadhesive tablets, Braz. arch. biol. technol., 53 (5): 1073-1085 (2010).
75. Mallikarjun V, Design and evaluation of Glipizide floating tablets, J. of Pharmacy Research, 2 (4): 691-693 (2009).
76. Kshirsagar RV, Jain V and Wattamwar S, Effect of different viscocity grade HPMC polymers on gastroretantive drug delivery of Metformin Hcl, Int. J. of App. Pharma., 1 (1): 44-50 (2009).
77. Raju DB, Sreenivas R, and Varma MM, Formulation and evaluation of floating drug delivery system of Metformin Hydrochloride, J. Chem. Pharm. Res., 2 (2): 274-278 (2010).
78. Ali J, Arora S, Ahuja A, Babbar AK, Sharma RK, Khar RK and Baboota S, Formulation and development of hydrodynamically balanced system for metformin: In vitro and in vivo evaluation, E. J. of Pharma. and Biopharma., 67: 196-201 (2007).